BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 15487901)

  • 1. Interaction of oxaliplatin, cisplatin, and carboplatin with hemoglobin and the resulting release of a heme group.
    Mandal R; Kalke R; Li XF
    Chem Res Toxicol; 2004 Oct; 17(10):1391-7. PubMed ID: 15487901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass spectrometric studies of cisplatin-induced changes of hemoglobin.
    Mandal R; Kalke R; Li XF
    Rapid Commun Mass Spectrom; 2003; 17(24):2748-54. PubMed ID: 14673822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mass spectrometry study of hemoglobin-oxaliplatin complexes in colorectal cancer patients and potential association with chemotherapeutic responses.
    Mandal R; Sawyer MB; Li XF
    Rapid Commun Mass Spectrom; 2006; 20(17):2533-8. PubMed ID: 16878345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of cytotoxicities of platinum compounds.
    Goodisman J; Hagrman D; Tacka KA; Souid AK
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interaction of platinum-based drugs with native biologically relevant proteins.
    Brauckmann C; Wehe CA; Kieshauer M; Lanvers-Kaminsky C; Sperling M; Karst U
    Anal Bioanal Chem; 2013 Feb; 405(6):1855-64. PubMed ID: 23052861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme.
    Casini A; Mastrobuoni G; Temperini C; Gabbiani C; Francese S; Moneti G; Supuran CT; Scozzafava A; Messori L
    Chem Commun (Camb); 2007 Jan; (2):156-8. PubMed ID: 17180231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic study on the reactions of platinum drugs with glutathione.
    Hagrman D; Goodisman J; Souid AK
    J Pharmacol Exp Ther; 2004 Feb; 308(2):658-66. PubMed ID: 14610218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin.
    Pendyala L; Creaven PJ
    Cancer Res; 1993 Dec; 53(24):5970-6. PubMed ID: 8261411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
    Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TCEP-based rSDS-PAGE AND nLC-ESI-LTQ-MS/MS for oxaliplatin metalloproteomic analysis.
    Mena ML; Moreno-Gordaliza E; Gómez-Gómez MM
    Talanta; 2013 Nov; 116():581-92. PubMed ID: 24148449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of major protein-protein and protein-metal complexes of erythrocytes directly from cell lysate utilizing capillary electrophoresis mass spectrometry.
    Nguyen A; Moini M
    Anal Chem; 2008 Sep; 80(18):7169-73. PubMed ID: 18710259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental study of renal disorder caused by oxaliplatin in rat renal cortical slices.
    Kanou T; Uozumi J; Soejima K; Tokuda Y; Masaki Z
    Clin Exp Nephrol; 2004 Dec; 8(4):310-5. PubMed ID: 15619029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients.
    Allain P; Heudi O; Cailleux A; Le Bouil A; Larra F; Boisdron-Celle M; Gamelin E
    Drug Metab Dispos; 2000 Nov; 28(11):1379-84. PubMed ID: 11038167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative measurement of the reduction of platinum(IV) complexes using X-ray absorption near-edge spectroscopy (XANES).
    Hall MD; Daly HL; Zhang JZ; Zhang M; Alderden RA; Pursche D; Foran GJ; Hambley TW
    Metallomics; 2012 Jun; 4(6):568-75. PubMed ID: 22569908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody.
    Tilby MJ; Johnson C; Knox RJ; Cordell J; Roberts JJ; Dean CJ
    Cancer Res; 1991 Jan; 51(1):123-9. PubMed ID: 1703029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of interaction between human hemoglobin A0 and platinum anticancer drugs by capillary isoelectric focusing with whole column imaging detection.
    Lemma T; Mandal R; Li XF; Pawliszyn J
    J Sep Sci; 2008 Jun; 31(10):1803-9. PubMed ID: 18446809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutathione modified CdTe quantum dots as a label for studying DNA interactions with platinum based cytostatics.
    Ryvolova M; Smerkova K; Chomoucka J; Hubalek J; Adam V; Kizek R
    Electrophoresis; 2013 Mar; 34(6):801-8. PubMed ID: 23400813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical Imaging of Platinum-Based Drugs and their Metabolites.
    Liu X; Hummon AB
    Sci Rep; 2016 Dec; 6():38507. PubMed ID: 27917942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intact human holo-transferrin interaction with oxaliplatin.
    Zhao YY; Mandal R; Li XF
    Rapid Commun Mass Spectrom; 2005; 19(14):1956-62. PubMed ID: 15954173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. East-west fusion-necrosis and apoptosis acting in concert by demethylcantharidin-integrated platinum complexes.
    Pang SK; So WK; Ho YP; Au-Yeung CF
    Anticancer Agents Med Chem; 2014 Jun; 14(5):756-61. PubMed ID: 24476313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.